Recent News

• 04.15.2025 - Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
• 04.03.2025 - Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
• 04.02.2025 - Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
• 03.24.2025 - Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
• 03.17.2025 - Sangamo Fourth Quarter 2024 Teleconference Call
• 03.17.2025 - Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
• 03.12.2025 - Barclays 27th Annual Global Healthcare Conference
• 03.11.2025 - Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
• 03.06.2025 - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
• 02.18.2025 - Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Recent Filings

• 03.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.17.2025 - 8-K Current report
• 03.17.2025 - EX-99.1 EX-99.1
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities